Skip to main content
. Author manuscript; available in PMC: 2023 Sep 28.
Published in final edited form as: Nat Rev Bioeng. 2023 Jan 30;1(2):107–124. doi: 10.1038/s44222-022-00016-2

Figure 4 |. Targeting systemic lymphoid organs.

Figure 4 |

Nanoparticle (NP) carriers can target lymphoid organs systemically, including lymph nodes, spleen, bone marrow and tolerogenic antigen presenting cells in the liver. For example, Apolipoprotein-based lipid nanodiscs a preferentially taken up by myeloid cells in the liver, spleen, and bone marrow. Stabilin-funcitonalized nanoparticles are efficiently scavenged by endothelial cells in the liver. Anionic LNPs target antigen presenting cells in the liver, spleen, lymph nodes, and bone marrow.